Cytokinetics has revealed the results from a phase 3 trial of its hypertrophic cardiomyopathy (HCM) drug aficamten that it hopes will allow it to compete with Bristol-Myers Squibb’s first-to-market ...

Cytokinetics may be counting down the days until the FDA decides whether to approve its cardiovascular drug aficamten. But, for a biotech planning to commercialize its first drug—and without Big ...

Bristol Myers Squibb announced the presentation of data from its cardiovascular portfolio at the American Heart Association’s ((AHA) Scientific Sessions 2025, taking place November 7–10, 2025 in New ...

NEW YORK - Bristol Myers Squibb (NYSE:BMY), a pharmaceutical giant with a market capitalization of $93.79 billion and currently considered undervalued according to InvestingPro analysis, will present ...

Bristol Myers Squibb (NYSE: BMY) today presented results from COLLIGO-HCM, a global retrospective real-world data study, in an oral session at the European Society of Cardiology (ESC) Congress 2025 in ...

Bristol Myers Squibb Presents Real-World Outcomes of Camzyos (mavacamten) Across Four Continents at the European Society of Cardiology (ESC) Congress 2025 Findings from COLLIGO-HCM reinforce Camzyos’ ...

Findings from COLLIGO-HCM reinforce Camzyos’ efficacy and safety profile in reducing left ventricular outflow tract (LVOT) obstruction and improving symptom burden in a racially diverse, global ...

Bristol Myers’ (BMY) cardiovascular portfolio currently comprises blockbuster drugs Eliquis and Camzyos. Blood thinner medicine Eliquis, for which BMY has a worldwide co-development and ...

Doctors prescribe Camzyos to treat obstructive hypertrophic cardiomyopathy with symptoms in adults. It’s available only under the Camzyos risk evaluation and mitigation strategy (REMS) program, a ...

Factors affecting Camzyos cost include your treatment plan, insurance coverage, pharmacy, and whether Camzyos has a savings program that you qualify for. The Camzyos Co-Pay Program is available for ...